早期宫颈癌前哨淋巴结活检与并发症结局:SENTICOL-2多中心随机试验结果
SENTICOL-2是一项开放标签多中心随机试验,纳入206例FIGO 2009 IA2-IIA1期早期宫颈癌患者,随机分为前哨淋巴结切除 alone 组(105例)与前哨淋巴结切除联合盆腔淋巴结清扫组(101例)。主要终点为淋巴结清扫相关并发症,3年无复发生存为次要终点。结果显示前哨淋巴结 alone 组淋巴系统并发症显著低于联合清扫组(31.4% vs 51.5%,p=0.0046),术后神经系统症状发生率亦显著降低(7.8% vs 20.6%,p=0.01),但两组显著淋巴水肿比例无显著差异,3年无复发生存无显著差异(92.0% vs 94.4%)。
要点
- 前哨淋巴结切除 alone 组淋巴系统并发症显著低于联合盆腔淋巴结清扫组(31.4% vs 51.5%,p=0.0046)。
- 前哨淋巴结切除 alone 组术后神经系统症状发生率显著低于联合清扫组(7.8% vs 20.6%,p=0.01)。
- 两组3年无复发生存无显著差异(92.0% vs 94.4%),联合清扫组未见假阴性病例。
核心结论
- 在早期宫颈癌中,与仅行前哨淋巴结切除相比,联合盆腔淋巴结清扫未带来生存获益,却增加早期淋巴系统并发症。
研究设计与样本
- 开放标签多中心随机试验,纳入206例FIGO 2009 IA2-IIA1期早期宫颈癌患者,随机分为前哨淋巴结切除 alone 组(105例)和前哨淋巴结切除联合盆腔淋巴结清扫组(101例)。
主要发现
- 前哨淋巴结切除 alone 组淋巴系统并发症发生率为31.4%,显著低于联合清扫组的51.5%(p=0.0046)。
- 前哨淋巴结切除 alone 组术后神经系统症状发生率为7.8%,显著低于联合清扫组的20.6%(p=0.01)。
- 两组显著淋巴水肿比例无显著差异,术后6个月内并发症差异随时间缩小。
- 3年无复发生存率在前哨淋巴结切除 alone 组为92.0%,联合清扫组为94.4%,无显著差异。
- 联合清扫组未观察到假阴性病例。
关键数值与推荐
- 主要终点为淋巴结清扫相关并发症,前哨淋巴结切除 alone 组31.4% vs 联合清扫组51.5%(p=0.0046)。
- 术后神经系统症状发生率7.8% vs 20.6%(p=0.01)。
- 3年无复发生存率92.0% vs 94.4%,无显著差异。
临床怎么用
- 早期宫颈癌患者可考虑仅行前哨淋巴结切除以降低早期淋巴系统并发症,但需注意显著淋巴水肿比例无差异及长期肿瘤学结局需进一步随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pelvic lymph node dissection has been the standard of care for patients with early cervical cancer. Sentinel node (SN) mapping is safe and feasible and may increase the detection of metastatic disease, but benefits of omitting pelvic lymph node dissection in terms of decreased morbidity have not been demonstrated. MATERIALS AND METHODS: In an open-label study, patients with early cervical carcinoma (FIGO 2009 stage IA2 to IIA1) were randomly assigned to SN resection alone (SN arm) or SN and pelvic lymph node dissection (SN + PLND arm). SN resection was followed by radical surgery of the tumour (radical hysterectomy or radical trachelectomy). The primary end-point was morbidity related to the lymph node dissection; 3-year recurrence-free survival was a secondary end-point. RESULTS: A total of 206 patients were eligible and randomly assigned to the SN arm (105 patients) or SN + PLND arm (101 patients). Most patients had stage IB1 lesion (87.4%). No false-negative case was observed in SN + PLND arm. Lymphatic morbidity was significantly lower in the SN arm (31.4%) than in the SN + PLND arm (51.5%; p = 0.0046), as was the rate of postoperative neurological symptoms (7.8% vs. 20.6%, p = 0.01, respectively). However, there was no significant difference in the proportion of patients with significant lymphoedema between the two groups. During the 6-month postoperative period, the difference in morbidity decreased over time. The 3-year recurrence-free survival was not significantly different (92.0% in SN arm and 94.4% in SN + PLND arm). CONCLUSION: SN resection alone is associated with early decreased lymphatic morbidity when compared with SN + PLND in early cervical cancer.
引用
- Mathevet P, Lécuru F, Uzan C, et al. Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2). Eur J Cancer. 2021. PMID: 33773275. doi:10.1016/j.ejca.2021.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。